ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.

Product information

CAS Number: 1360705-96-9

Molecular Weight: 475.32

Formula: C22H20Cl2N4O4

Chemical Name: 1-[bis(4-chlorophenyl)methyl]-4-(5-methyl-4-nitro-1, 2-oxazole-3-carbonyl)piperazine

Smiles: CC1ON=C(C=1[N+]([O-])=O)C(=O)N1CCN(CC1)C(C1C=CC(Cl)=CC=1)C1C=CC(Cl)=CC=1

InChiKey: VIBHJPDPEVVDTB-UHFFFAOYSA-N

InChi: InChI=1S/C22H20Cl2N4O4/c1-14-20(28(30)31)19(25-32-14)22(29)27-12-10-26(11-13-27)21(15-2-6-17(23)7-3-15)16-4-8-18(24)9-5-16/h2-9,21H,10-13H2,1H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 25 mg/mL (52.60 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

ML-210 exhibits cell-killing activity across a panel of 821 cancer cell lines (WM88, LOX-IMVI, CJM, U257, CAKI2, A498, HT1080, MC38, PANC02). ML-210 is a prodrug that requires cellular activation to bind GPX4. ML-210 has IC50s of 71 nM, 272 nM and 107nM for BJeLR (HRASV12), BJeH-LT (without HRASV12) and DRD cell lines, respectively.

References:

1. John K. Eaton, et al. Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors. Biorxiv. 2018.
2. Weïwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6.

Products are for research use only. Not for human use.